The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis.

For semaglutide, pooled data from three studies, including patients with HFrEF, suggested a marginally significant benefit for HFH and CV mortality (RR: 0.83, 95% CI: 0.69–1.00; Cochran’s Q test, p = 0.51; I 2 = 0%) [ 23 , 24 , 25 ].

also in 26,082 other papers

While a reduction in all-cause mortality was observed, the results did not reach statistical significance, suggesting a potential but inconclusive survival benefit.

also in 111,027 other papers